Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Hoff

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|August 30, 2008
A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancerP M Hoff, S Kopetz, M B Thomas, et al.
British Journal of Cancer|October 24, 2013
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapyS K M Spencer, A J C Pommier, S R Morgan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analogM E Royce, P M Hoff, P Dumas, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancerY Y Janjigian, E Smyth, L Shen, et al.
British Journal of Cancer|August 15, 2014
Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranibA J C Pommier, R Shaw, S K M Spencer, et al.
Investigational New Drugs|July 30, 1999
Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinomaR Pazdur, D C Medgyesy, R J Winn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancerP M Hoff, N Janjan, E D Saad, et al.
Clinical Pharmacology and Therapeutics|December 17, 2008
A dynamic model of hand-and-foot syndrome in patients receiving capecitabineE Hénin, B You, E VanCutsem, et al.
Cancer|May 17, 2000
Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapyP M Hoff, V Valero, A U Buzdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III studyP M Hoff, R Ansari, G Batist, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|August 30, 2008
A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancerP M Hoff, S Kopetz, M B Thomas, et al.
British Journal of Cancer|October 24, 2013
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapyS K M Spencer, A J C Pommier, S R Morgan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analogM E Royce, P M Hoff, P Dumas, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancerY Y Janjigian, E Smyth, L Shen, et al.
British Journal of Cancer|August 15, 2014
Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranibA J C Pommier, R Shaw, S K M Spencer, et al.
Investigational New Drugs|July 30, 1999
Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinomaR Pazdur, D C Medgyesy, R J Winn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancerP M Hoff, N Janjan, E D Saad, et al.
Clinical Pharmacology and Therapeutics|December 17, 2008
A dynamic model of hand-and-foot syndrome in patients receiving capecitabineE Hénin, B You, E VanCutsem, et al.
Cancer|May 17, 2000
Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapyP M Hoff, V Valero, A U Buzdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III studyP M Hoff, R Ansari, G Batist, et al.
Pageof 5